Furthermore, tumor immunostaining showed that EZH2 inhibition reduced cell proliferation (MKI67), increased cell death (cleaved Caspase-3 [CC3]), and restored MHC-I expression in CRPR2 tumors (Fig. 4n). Here, CASP3 is linked to neoplasm.